Table 1.
Baseline demographic and clinical variables among patients with cancer and COVID-19 according to vaccination status.
| Unvaccinated (n = 1537) | 2 doses of mRNA vaccines (n = 564) | 3 doses of mRNA vaccines (n = 385) | |
|---|---|---|---|
| Age, median years (IQR) | 64.0 (53.0–74.0) | 66.0 (57.0–75.0) | 67.0 (59.0–76.0) |
| Sex | |||
| Male | 656 (42%) | 252 (47%) | 209 (49%) |
| Female | 880 (58%) | 311 (53%) | 176 (51%) |
| Missing | 1 (<1%) | 1 (<1%) | 0 |
| Race & ethnicity | |||
| Non-Hispanic White | 896 (58%) | 400 (71%) | 284 (74%) |
| Non-Hispanic Black | 287 (19%) | 71 (13%) | 46 (12%) |
| Hispanic or Latino | 176 (11%) | 38 (7%) | 25 (6%) |
| Other | 149 (10%) | 46 (8%) | 19 (5%) |
| Unknown or missing | 29 (2%) | 9 (2%) | 11 (3%) |
| ECOG PS | |||
| 0 | 464 (30%) | 175 (31%) | 160 (42%) |
| 1 | 424 (28%) | 177 (31%) | 116 (30%) |
| ≥2 | 211 (14%) | 96 (17%) | 55 (14%) |
| Unknown or missing | 438 (28%) | 116 (21%) | 54 (14%) |
| mCCI | |||
| 0 | 748 (49%) | 266 (47%) | 202 (52%) |
| 1 | 368 (24%) | 134 (24%) | 80 (21%) |
| ≥2 | 406 (26%) | 159 (28%) | 99 (26%) |
| Unknown or missing | 15 (1%) | 5 (<1%) | 4 (1%) |
| Smoking status | |||
| Never (non-smoker) | 743 (48%) | 249 (44%) | 189 (49%) |
| Current or former smoker | 734 (48%) | 300 (53%) | 182 (47%) |
| Unknown or missing | 60 (4%) | 15 (3%) | 14 (4%) |
| Cancer type | |||
| Solid organ tumour | 1174 (76%) | 390 (69%) | 226 (59%) |
| Hematologic malignancy | 312 (20%) | 149 (26%) | 128 (33%) |
| Both | 51 (3%) | 25 (4%) | 31 (8%) |
| Cancer status | |||
| Active and progressing | 240 (15%) | 93 (16%) | 52 (14%) |
| Not active or progressing | 1130 (74%) | 406 (72%) | 300 (78%) |
| Unknown or missing | 167 (11%) | 65 (12%) | 33 (9%) |
| Recent systemic anti-cancer therapy | |||
| Yes | 663 (43%) | 287 (51%) | 221 (57%) |
| No | 861 (56%) | 269 (48%) | 162 (42%) |
| Unknown or missing | 13 (1%) | 8 (1%) | <5 (1%) |
| Baseline corticosteroids | |||
| None | 1291 (84%) | 454 (81%) | 305 (79%) |
| ≤10 mg/day PDE | 82 (5%) | 35 (6%) | 28 (7%) |
| >10 mg/day PDE | 121 (8%) | 56 (10%) | 38 (10%) |
| Unknown or missing | 43 (3%) | 19 (3%) | 14 (4%) |
| Lymphopenia | |||
| Yes | 549 (36%) | 197 (35%) | 92 (24%) |
| No | 322 (21%) | 94 (17%) | 57 (17%) |
| Unknown or missinga | 666 (43%) | 273 (48%) | 236 (61%) |
| Type of vaccine received | |||
| BNT162b2 | 0 | 366 (65%) | 234 (61%) |
| mRNA-1273 | 0 | 193 (34%) | 142 (37%) |
| Unspecified, including multiple types (“mix and match”) | 0 | 5 (1%) | 9 (2%) |
ECOG PS: Eastern Cooperative Oncology Group performance status; mCCI: modified Charlson comorbidity index; PDE: prednisone dose equivalent; US: United States.
a
This includes a substantial number of cases where labs were not drawn, as is typically the case for milder cases of COVID-19.